The EPS miss may pressure the stock near-term, but the ongoing strategic review and restructuring progress provide upside optionality. Monitor for updates on the sale process and Q2 2026 operating expense reductions.
TBPH drugs
TBPH drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $17.02entry
- T+1 · 6mo ago −0.06%α −0.89% · $17.01
- T+5 · 6mo ago −2.06%α −3.56% · $16.67
- T+20 · 6mo ago −6.46%α −9.60% · $15.92
- T+60 · 4mo ago −0.88%α −4.71% · $16.87
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theravance Biopharma reported Q1 2026 revenue of $17.7M (+15% YoY), slightly above the $17.4M consensus, but GAAP EPS of -$0.10 missed the Street estimate of -$0.05. Net loss improved to -$4.9M from -$13.6M a year ago, and non-GAAP net income turned positive at $0.6M. The company reaffirmed its restructuring and cost-cutting targets, while the strategic review for a potential sale continues.
Key Financial Metrics
Key Facts
- Total revenue $17.7M, up 15% YoY from $15.4M, entirely from Viatris collaboration
- GAAP net loss per share -$0.10 vs. consensus -$0.05 (100% miss)
- Net loss narrowed to $4.9M from $13.6M in Q1 2025
- Non-GAAP net income from operations was $0.6M vs. -$8.6M last year
- Cash & marketable securities $394.7M as of March 31, 2026, no debt
- Operating expenses (excl. restructuring) down ~20% YoY; restructuring on track for $60-70M annualized cash flow by Q3 2026
- Strategic Review Committee actively evaluating options including a sale
Financial Impact
EPS miss of $0.05 vs. consensus, revenue beat of $0.3M; net loss improvement of $8.7M YoY is overshadowed by the EPS shortfall
Risk Factors
- Strategic review may not result in a transaction or may be delayed
- Failure to achieve $100M TRELEGY milestone if GSK sales fall below $3.5B
- Execution risk in achieving full restructuring savings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-056733 |
| Document: tm2613884d1_8k.htm | 0001104659-26-056733 |
| Document: 0001104659-26-056733-index-headers.html | 0001104659-26-056733 |
| Document: 0001104659-26-056733-index.html | 0001104659-26-056733 |
| Document: 0001104659-26-056733.txt | 0001104659-26-056733 |
| 8-K Data (Synthetic) | 0001104659-26-056733 |
Track record
12 reports on TBPH
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +2.11% at T+1 after the Mar 3, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry price pending
- Oct 5, 20266w ago 15-12G Bearish 7/10 No price data
- Sep 25, 20267w ago SC 13D/A Neutral 4/10 Entry $17.04 No price data
- Sep 23, 20267w ago 25-NSE Bearish 7/10 Entry $17.05 No price data
- Aug 25, 202611w ago DEFA14A Neutral 4/10 Entry $17.03 to $17.03 · 0.00% −0.23% vs SPY
- Aug 21, 202612w ago DEFM14A Bullish 7/10 Entry $17.01 to $17.05 ▲ +0.24% +0.76% vs SPY
- Aug 11, 202613w ago PREM14A Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.95% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.80% vs SPY
- Jun 29, 202620w ago 8-K Bullish 7/10 Entry $17.06 to $16.86 ▼ −1.17% −0.89% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $17.27 to $16.81 ▼ −2.66% −4.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers